Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 5/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6270879 | 0.91 | GAA (0.39) | GAATAS1R3TAS1R1CASRTACR1 | |
| SCHEMBL1361676 | 0.88 | SMN1; SMN2 (0.51) | GAANPC1RAB9A | |
| SCHEMBL6266202 | 0.79 | SMN1; SMN2 (0.51) | GAANPC1RAB9A | |
| SCHEMBL1362244 | 0.78 | CYP3A4 (0.47) | TACR1TACR3 | |
| SCHEMBL6617399 | 0.77 | ACE (0.46) | — | |
| SCHEMBL1362522 | 0.77 | TACR1 (0.55) | TACR1TACR3GPR88 | |
| SCHEMBL6158896 | 0.76 | GPR88 (0.39) | TACR1TACR3TP53GPR88 | |
| SCHEMBL2945634 | 0.74 | MME (0.48) | — | |
| SCHEMBL5741002 | 0.74 | CNR1 (0.39) | TACR1TACR3 | |
| SCHEMBL6158939 | 0.73 | F10 (0.38) | GAATACR1TACR3TP53GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067584-B2 | Benzothiazepine derivatives | ALBIREO AB (SE) | 2011-11-29 | — | — | US | disclosed |
| EP-1430040-B1 | BENZOTHIAZEPINE DERIVATIVES | ALBIREO AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| US-7192946-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | ALBIREO AB (SE) | 2006-05-04 | — | — | US | disclosed |
| US-20040254160-A1 | Benzothiazepine derivatives | ELOBIX AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1430040-A1 | BENZOTHIAZEPINE DERIVATIVES | Astrazeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003020710-A1 | BENZOTHIAZEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254160-A1 | Benzothiazepine derivatives | SLC10A2, SLC10A1, ABCB11 | GAA 1070/4885TAS1R3 1026/4885TAS1R1 838/4885 |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | SLC10A2, SLC10A1, ABCB11 | GAA 1321/4885TAS1R3 902/4885TAS1R1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.